Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
You may also be interested in...
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.